TITLE: COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE

ABSTRACT: The invention relates generally to peptides comprising one or more non-natural amino acids residues and their use in cosmetic and personal care compositions.
COMPOSITIONS CONTAINING PEPTIDES
WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE

This application claims priority to U.S. provisional patent application Ser. No. 60/777,412, filed February 28, 2006, the contents of which are hereby incorporated by reference in their entirety.

FIELD OF INVENTION

The invention relates generally to peptides comprising one or more non-natural amino acids residues and their use in cosmetic and personal care compositions.

BACKGROUND OF THE INVENTION

A variety of natural and synthetic peptides have found widespread use in cosmetic compositions. Typically, peptides are included in cosmetics for their functional attributes such as enzyme inhibition, antiviral and antibacterial activity. Examples of the use of peptides in cosmetic applications are provided in the following literature.

U.S. Patent Publication No. 2005/0142092 A1 describes cosmetic compositions comprising hesperidin and an angiotensin converting enzyme (ACE) inhibitor dipeptide, such as H-Val-Trp-OH, or an oligopeptide, exemplified by H-Gly-Gln-Pro-Arg-OH or palmitoyl-Gly-Gln-Pro-Arg-OH, stated to be useful for reducing bags and circles under the eyes.

U.S. Patent Publication No. 2005/0124545 A1 relates to the use of a family of peptides, such as Arg-Asp-Phe-Thr-Lys-Ala-Thr-Asn-Ile-Arg-Leu-Arg-Phe-Leu-Arg, in cosmetic compositions. The peptides are said to reduce cutaneous aging.

U.S. Patent Publication No. 2004/0229808 A1 discloses skin care compositions comprising a peptide of 5 to 22 amino acids having at least 50% phenylalanine, leucine, alanine, and lysine residues (FLAK peptides), for antibacterial, antifungal, anticancer, stimulation and proliferation applications, and wound healing applications.
U.S. Patent Publication No. 2004/0141939 A1 discloses peptides comprising the sequence Leu-Asp-Ala-Pro, as exemplified by Lys-Leu-Asp-Ala-Pro-Thr, and their cosmetic and dermatological applications. The peptides are said to promote adhesion between skin cells and cure or prevent symptoms of ageing skin.

U.S. Patent Publication No. 2004/0120918 A1 provides cosmetic compositions comprising a polypeptide having anti-aging activity and a ceramide capable of providing an improvement in the anti-aging activity of the polypeptide. The peptides have an amino acid sequence of from 3 to 12 amino acids in length, such as Val-Gly-Val-Ala-Pro-Gly.

U.S. Patent No. 6,821,524 describes the use of the small, naturally occurring polypeptide thymosin-beta-4 (TB4) in cosmetic compositions for improving the appearance of aged or damaged skin. Vascular endothelial growth factor (VEGF) and transforming growth factor beta 1 (TGFB) peptides are also stated to be useful for inclusion in the described cosmetic compositions.

U.S. Patent No. 6,852,699 discloses the use of peptides based on the structure Val-Val-Arg-Pro for treating undesired skin pigmentation.


U.S. Patent No. 6,620,419 discloses cosmetic compositions comprising polypeptides, exemplified by Lys-Thr-Thr-Lys-Ser, which are stated to induce synthesis of collagen and glycosaminoglycans to treat skin aging.

U.S. Patent No. 6,372,717 discloses cosmetic compositions comprising synthetic lipophile derivatives of Tyr-Arg peptides, including N-Acetyl-L-Tyr-L-Arg-O-hexadecyl, for relieving sensations of irritation, mild pain, effects of heat, cold, abrasion or mechanical attacks on the skin.
U.S. Patent No. 6,245,342 discloses the use in cosmetic compositions of peptides comprising His-Phe-Arg-Trp derived from α-MSH (melanocyte stimulating hormone). The cosmetic compositions are stated to have melanogenesis-stimulating and anti-inflammatory properties.

U.S. Patent No. 6,358,929 describes the use of a peptide containing the sequence Lysine-Proline-Valine as an additive in cosmetic compositions for preventing or reducing the intolerance reactions linked to a contact hypersensitivity.

U.S. Patent No. 6,235,291 describes the use of the peptides sendide (Tyr D-Phe Phe D-His Leu Met NH₂) and spantide II (D-NicLys Pro 3-Pal Pro D-Cl₂ Phe Asn D-Trp Phe D-Trp Leu Nle NH₂) as Substance P antagonists in cosmetic products for treating sensitive skin.

U.S. Patent No. 6,235,291 relates to the use of a peptide (Gly ᵇ Gly Asp Pro Val Thr Cys Leu Lys Ser Gly Ala ᵆ Cys His Pro Val Phe Cys Pro Arg Arg Tyr Lys Gln ᵇ Gly Thr Cys Gly Leu Pro Gly Thr Thr Cys Cys Lys Lys Pro) having activity against bacteria, mycota and/or viruses and its use in cosmetic compositions.

Other peptide additives for cosmetic compositions include soya peptides for inhibiting elastase, plant peptides for inhibiting collagenase, copper complexes of peptides such as glycyl-L-histidyl-L-lysine, L-valyl-L-histidyl-L-lysine, and L-alanyl-L-histidyl-L-lysine (U.S. Patent Publication No. 2003/0148927), ovotransferrin peptides for inhibiting proteases which degrade elastin or collagen, and the anti-wrinkle peptides acetyl hexapeptide-3 having the structure acetyl glutamyl-glutamyl-methyonyl-glutamyl-arginyl-arginylamide (U.S. Patent Publication No. 2005/01 18124 A1), palmitoyl oligopeptide and palmitoyl pentapeptide-3 having the sequence Lys-Thr-Thr-Lys-Ser.

Other interesting peptides are described in, for example, U.S. Patent Nos. 6,566,330, 6,060,043 and 6,566,115, U.S. Patent Publication No. 2005/0187164 A1 and 2005/0148495 A1, and published PCT applications WO 2005/097060 A1 and WO 03/086313 A2, the disclosures of which are hereby incorporated by reference.
Despite the desirability of incorporating peptides in cosmetics, there are certain disadvantages associated with their use. For example, active peptide agents may suffer from poor efficacy of use due to, for instance, their conformational flexibility and/or the easy digestion of peptides by proteases at the sites of intended action. Further, efficacy may be hindered due to the difficulty with which peptides are transported across membranes such as skin and their poor solubility in many cosmetic vehicles. Additionally, the risk of immunogenic reaction to peptides also presents a concern in cosmetic formulation.

It is therefore an object of the invention to provide novel peptides for cosmetic applications which provide enhanced efficacy.

It is another object of the invention to provide novel peptides for cosmetic applications which provide resistance to proteolytic degradation.

It is yet another object of the invention to provide novel peptides for cosmetic applications which decrease the risk of immunogenic reaction.

SUMMARY OF INVENTION

In accordance with the foregoing objectives and others, the present invention provides novel peptides comprising one or more non-naturally occurring amino acids having cosmetically beneficial properties.

One aspect of the invention provides peptides comprising non-natural amino acids having the sequence of formula I:

\[(AA)n\cdot X\cdot(\text{AA'})m\]

where AA and AA' are independently an amino acid or peptide comprising amino acids selected from the naturally occurring amino acids L-alanine, L-valine, L-leucine, L-isoleucine, L-proline, L-tryptophan, L-phenylalanine, L-methionine, glycine, L-serine, L-tyrosine, L-threonine, L-cysteine, L-asparagine, L-glutamine, L-aspartic acid, L-glutamic acid, L-lysine, L-arginine, and L-histidine;

"n" and "m" are independently an integer from 0 to about 20; and
X represents a non natural amino acid of formula II or a peptide fragment comprising one or more non natural amino acids of formula II optionally including one or more natural amino acids:

where Ri represents a peptide bond to an adjacent amino acid of the group AA' or, in the case of cyclic peptides, Ri represents a peptide bond to the terminal residue of the group AA or an amino-functionalized side chain of a residue within the group AA, or where X is a terminal amino acid residue of the type \( m=0 \), \( R_1 \) is typically hydroxyl, but may be any other functionality, including, for example, hydrogen, a protecting group, activating group or a lipophilic group such as a moiety selected from the group consisting of substituted or unsubstituted \( \text{C}_1 \) to \( \text{C}_{10} \) branched, straight chain, or cyclic alkoxy, aryl, and the like;

\( R_2 \), when present, provides amino acids having \( \text{NH}_2 \) groups on carbons atoms other than the \( \alpha \)-carbon (the carbon atom adjacent the carboxyl group), including for example, the \( \beta \) or \( \gamma \) carbons, and may therefore be any spacer group and in particular a moiety selected from the group consisting of substituted or unsubstituted branched or straight chain \( \text{Ci-C}_6 \) alkyl, alkenyl, alkynyl, aryl, heteroaryl, or alkyl-aryl groups, including without limitation, linear alkyl moieties of the form -(CH\(_2\))\( a \)- where "a" is an integer from 1 to 10, including, for example, -(CH\(_2\))-, -(CH\(_2\)\(_2\))-, -(CH\(_2\)CO\(_2\)H)-, or -(CH\(_2\)\(_2\)CH\(_2\)CH\(_2\)H)-; linear alkoxy moieties of the general form -(CH\(_2\))\( a \)O- or -O(CH\(_2\))\( a \)- where "a" is an integer from 1 to 10, including for example, -(CH\(_2\)O)- or -OCH\(_2\)-, -(CH\(_2\)CH\(_2\)O)- or -OCH\(_2\)CH\(_2\)-, -(CH\(_2\)\(_2\)CH\(_2\)O)- or -OCH\(_2\)\(_2\)CH\(_2\)-; -(CH\(_2\))\( a \)O- where "a" is as defined above; or a moiety of the form -(CH\(_2\))\( b \)O(CH\(_2\))\( c \)-, -(CH\(_2\))\( b \)S(CH\(_2\))\( c \)-, or -(CH\(_2\))\( b \)NR\(^a\)(CH\(_2\))\( c \)- wherein "b" and "c" are independently an integer from O(zero) to 10 and \( R^a \) is an alkyl, alkenyl, alkynyl, aryl, heteroaryl, or alkyl-aryl group;

"i" represents an integer from 0 (zero) to 3;
R3 and R4 may independently represent bonds to adjacent amino acids or may independently selected from the group consisting of hydrogen, substituted or unsubstituted branched or straight chain C1-C20 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkyl-aryl groups, acyl, or N-protecting groups, and will preferably be hydrogen, methyl, ethyl, propyl, acetyl, or, in the case where X is a terminal residue of the type n=0, R3 and R4 are each preferably hydrogen, acetyl, N-protecting group, or a lipophilic group such as a moiety selected from the group consisting of substituted or unsubstituted Ci to C20 branched, straight chain, or cyclic alkyl, alkenyl, aryl, heteroaryl, and the like or substituted or unsubstituted C1 to C20 branched or straight chain acyl; or R3 and R4 together may from a cyclic alkyl, aryl, heteroalkyl, or heteroaryl, group having between 3 and 6 carbon atoms; or R3 and R4 may independently, together with R2 or Ω form a cyclic alkyl, aryl, heteroalkyl, or heteroaryl, group having between 3 and 6 carbon atoms;

Ω is selected from hydrogen; hydroxyl; amino; halogen; caboxy, carboxamide, substituted or unsubstituted branched, straight chain or cyclic C1-C20 alkyl, alkenyl, alkynyl, aryl, benzyl, heteroaryl, alkyl-aryl, aryl-alkyl, alkyl-heteroaryl, heteroaryl-alkyl, heteroaryl-aryl, bicyclic alkyl, aryl, or heteroaryl, and combinations thereof; wherein the foregoing radicals may be substituted with any moiety, including, for example, alkyl, alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, hydroxyl; amino; cyano; halogen; oxo, oxa, caboxy, carboxamide, and combinations thereof;

with the proviso that X does not represent solely a naturally occurring amino acid in the case where neither AA or AA' comprise a non-naturally occurring amino acid of formula II.

In another interesting embodiment of the peptides of formula I, AA and AA' may independently represent a non-naturally occurring amino acid of formula II, or AA and AA' may independently represent a peptide fragment comprising one or more non-naturally occurring amino acids defined by formula II. In a further embodiment, any of AA, AA', and X may further include spacer groups which are not amino acids disposed between adjacent amino acid residues. When present, the spacer groups are typically selected from substituted or unsubstituted branched or straight chain Ci-C6 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkyl-aryl, alkyl-aryl-alkyl,
and aryl-alkyl-aryl groups, including without limitation, linear alkyl moieties of the form -(CH₂)ₐ where "a" is an integer from 1 to 20, including, for example, -CH₂-, -CH₂CH₂-, or -CH₂CH₂CH₂₂; linear alkoxy moieties of the general form -(CH₂)ₐO- or -O(CH₂)ₐ where "a" is an integer from 1 to 20, including for example, -CH₂O- or -OCH₂-, -CH₂CH₂O- or -OCH₂CH₂-, -CH₂CH₂CH₂O- or -OCH₂CH₂CH₂₂; -O(CH₂)ₐO- where "a" is as defined above; or a moiety of the form -(CH₂)bO(CH₂)c-, -(CH₂)bS(CH₂)c-, or -(CH₂)bNRₐ(CH₂)c- wherein "b" and "c" are independently an integer from 0 (zero) to 20 and Rₐ is an optionally substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, or alkyl-aryl group; and wherein the spacer group optionally includes fictionalization at either terminal end, or both terminal ends, with functional groups selected from the group consisting of -O-, -S-, -NRₐ-, -NRₐ-(C=O)-, -O-(C=O)-, -O-(SO₂)₂- and -0-(SO₂)₂-, where Rₐ is as defined above.

In another aspect of the invention, peptides are selected from the groups consisting of: (i) peptides comprising one or more amino acids of formula II; (ii) peptides comprising only amino acids of formula II; (iii) peptides comprising one or more amino acids of formula II and further including one or more spacer moieties as defined above; and (iv) peptides comprising only amino acids of formula II and further including one or more spacer moieties as defined above.

Another aspect of the invention provides cosmetic compositions for topical use comprising one or more of the peptides of the invention in a cosmetically acceptable carrier.

Yet another aspect of the invention provides a method for ameliorating and/or preventing signs of human skin photo- and intrinsic aging comprising topically applying the cosmetic compositions of the invention to the skin.

These and other aspects of the present invention will become apparent to those skilled in the art after a reading of the following detailed description of the invention, including the illustrative embodiments and examples.

DETAILED DESCRIPTION

As used herein, all terms are intended to have their ordinary meaning in the art unless specifically defined. The term "amino acid" is intended to include
naturally occurring amino acids as well as non-naturally occurring amino acids and expansively includes any small molecule having at least one carboxyl group and at least one primary or secondary amine group capable of forming a peptide bond. The term "peptide" is intended to include any molecule having at least one peptide bond and therefore includes di-peptides, tri-peptides, oligopeptides, and polypeptides having up to about 20 amino acid residues. The term "peptide" also embraces structures having one or more linkers, spacers, or terminal groups which are not amino acids.

i. Peptides

The peptides of the invention have the sequence of formula I:

$$(AA)_n-X-(AA')_n$$

where AA and AA' are independently an amino acid or peptide comprising amino acids selected from the naturally occurring amino acids shown in Table 1:

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>Structure</th>
<th>Three-letter code</th>
<th>Single-letter code</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-alanine</td>
<td><img src="image" alt="Structure of L-alanine" /></td>
<td>Ala</td>
<td>A</td>
</tr>
<tr>
<td>L-valine</td>
<td><img src="image" alt="Structure of L-valine" /></td>
<td>Val</td>
<td>V</td>
</tr>
<tr>
<td>L-leucine</td>
<td><img src="image" alt="Structure of L-leucine" /></td>
<td>Leu</td>
<td>L</td>
</tr>
<tr>
<td>Amino Acid</td>
<td>Structure</td>
<td>Abbreviation</td>
<td>Code</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>L-isoleucine</td>
<td><img src="image" alt="Structure" /></td>
<td>Ile</td>
<td>I</td>
</tr>
<tr>
<td>L-proline</td>
<td><img src="image" alt="Structure" /></td>
<td>Pro</td>
<td>P</td>
</tr>
<tr>
<td>L-tryptophan</td>
<td><img src="image" alt="Structure" /></td>
<td>Trp</td>
<td>W</td>
</tr>
<tr>
<td>L-phenylalanine</td>
<td><img src="image" alt="Structure" /></td>
<td>Phe</td>
<td>F</td>
</tr>
<tr>
<td>L-methionine</td>
<td><img src="image" alt="Structure" /></td>
<td>Met</td>
<td>M</td>
</tr>
<tr>
<td>Glycine</td>
<td><img src="image" alt="Structure" /></td>
<td>Gly</td>
<td>G</td>
</tr>
<tr>
<td>L-serine</td>
<td><img src="image" alt="Structure" /></td>
<td>Ser</td>
<td>S</td>
</tr>
<tr>
<td>L-tyrosine</td>
<td><img src="image" alt="Structure" /></td>
<td>Tyr</td>
<td>Y</td>
</tr>
<tr>
<td>L-threonine</td>
<td><img src="image" alt="Structure" /></td>
<td>Thr</td>
<td>T</td>
</tr>
</tbody>
</table>
wherein each of AA and AA' may independently represent homopolymers of one amino acid from Table 1 or may independently represent heteropolymers of different amino acids selected from Table 1:

<table>
<thead>
<tr>
<th>Amino Acid</th>
<th>Structure</th>
<th>Code</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-cysteine</td>
<td><img src="image" alt="Structure" /></td>
<td>Cys</td>
<td>C</td>
</tr>
<tr>
<td>L-asparagine</td>
<td><img src="image" alt="Structure" /></td>
<td>Asn</td>
<td>N</td>
</tr>
<tr>
<td>L-glutamine</td>
<td><img src="image" alt="Structure" /></td>
<td>Gin</td>
<td>Q</td>
</tr>
<tr>
<td>L-aspartic acid</td>
<td><img src="image" alt="Structure" /></td>
<td>Asp</td>
<td>D</td>
</tr>
<tr>
<td>L-glutamic acid</td>
<td><img src="image" alt="Structure" /></td>
<td>Glu</td>
<td>E</td>
</tr>
<tr>
<td>L-lysine</td>
<td><img src="image" alt="Structure" /></td>
<td>Lys</td>
<td>K</td>
</tr>
<tr>
<td>L-arginine</td>
<td><img src="image" alt="Structure" /></td>
<td>Arg</td>
<td>R</td>
</tr>
<tr>
<td>L-histidine</td>
<td><img src="image" alt="Structure" /></td>
<td>His</td>
<td>H</td>
</tr>
</tbody>
</table>

wherein each of AA and AA' may independently represent homopolymers of one amino acid from Table 1 or may independently represent heteropolymers of different amino acids selected from Table 1;
"n" and "m" are independently an integer from 0 to about 20; preferably integers from 0 to about 10; and more preferably integers from 0 to about 5;

X represents a non natural amino acid of formula I or a peptide fragment comprising one or more non natural amino acids of formula I optionally including one or more natural amino acids:

![Chemical structure](image)

where Ri represents a peptide bond to an adjacent amino acid of the group AA' or, in the case of cyclic peptides, Ri represents a peptide bond to the terminal residue of the group AA or an amino-functionalized side chain of a residue within the group AA, or where X is a terminal amino acid residue of the type m=0. Ri is typically hydroxyl, but may be any other functionality, including, for example, hydrogen, a protecting group, activating group or a lipophilic group such as a moiety selected from the group consisting of substituted or unsubstituted C1 to C20 branched, straight chain, or cyclic alkoxy, aryloxy, and the like;

R2, when present, provides amino acids having NH2 groups on carbons atoms other than the α-carbon (the carbon atom adjacent the carboxyl group), including for example, the β or γ carbons, and may therefore be any spacer group and in particular a moiety selected from the group consisting of substituted or unsubstituted branched or straight chain C1-Ce alkyl, alkenyl, alkynyl, aryl, heteroaryl, or alkyl-aryl groups, including without limitation, linear alkyl moieties of the form -(CH2)a where "a" is an integer from 1 to 10, including, for example, -CH2-, -CH2CH2-, -CH2CH2CH2-, or -CH2CH2CH2CH2-; linear alkoxy moieties of the general form -(CH2)aO- or -O(CH2)a- where "a" is an integer from 1 to 10, including for example, -CH2O- or -OCH2-, -CH2CH2O- or -OCH2CH2-, -CH2H2CH2H2O- or -OCH2CH2CH2-; -O(CH2)aO- where "a" is as defined above; or a moiety of the form -(CH2)bO(CH2)c- , -(CH2)bS(CH2)c- , or -(CH2)bNRa(CH2)c- wherein "b" and "c" are independently an integer from 0 (zero) to 10 and Ra is an alkyl, alkenyl, alkynyl, aryl, heteroaryl, or alkyl-aryl group, and the like. Preferably, R2, when present, is -CH2-Or-CH2CH2-;
"i" represents an integer from 0 (zero) to 3 and will be zero where the amino acid has the α-amino configuration of a natural amino acid;

R₃ and R₄ may independently represent bonds to adjacent amino acids or may independently selected from the group consisting of hydrogen, substituted or unsubstituted branched or straight chain C1-C20 alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkyl-aryl groups, acyl, or N-protecting groups, and will preferably be hydrogen, methyl, ethyl, propyl, acetyl, or, in the case where X is a terminal residue of the type n=0, R₃ and R₄ are each preferably hydrogen, acetyl, N-protecting group, or a lipophilic group such as a moiety selected from the group consisting of substituted or unsubstituted C₁ to C₂₀ branched, straight chain, or cyclic alkyl, alkenyl, aryl, heteroaryl, and the like or substituted or unsubstituted C₁ to C₂₀ branched or straight chain acyl; or R₃ and R₄ together may from a cyclic alkyl, aryl, heteroalkyl, or heteroaryl, group having between 3 and 6 carbon atoms; or R₃ and R₄ may independently, together with R₂ or Ω form a cyclic alkyl, aryl, heteroalkyl, or heteroaryl, group having between 3 and 6 carbon atoms (analogous to the natural amino acid proline);

Ω is selected from hydrogen; hydroxyl; amino; halogen; caboxy, carboxamide, substituted or unsubstituted branched, straight chain or cyclic C₁-C₂₀ alkyl, alkenyl, alkynyl, aryl, benzyl, heteroaryl, alkyl-aryl, aryl-alkyl, alkyl-heteroaryl, heteroaryl-alkyl, heteroaryl-aryl, bicyclic alkyl, aryl, or heteroaryl, and combinations thereof; wherein the foregoing radicals may be substituted with any moiety, including, for example, alkyl, aryl, heteroaryl, hydroxyl; amino; cyano; halogen; oxo, oxa, caboxy, carboxamide, and combinations thereof; with the proviso that X does not represent a naturally occurring amino acid.

Ω may be selected from or may include one or more substituents selected from the group consisting of aceanthrenyl, aceanthrylenyl, acenaphthenyl, acenaphthenylene, acenaphthenylidene, acenaphthylenyl, acephenanthrenyl, acephenanthrylenyl, acetamido, acetimidoyl, acetoacetyl, acetohydrazonoyl, acetohydroximoyl, acetonyl, acetonilidene, acetoxy, acetyl, acetylamino, acetylhydrazino, acetylmino, acridinyl, acryloyl, adipoyl, alanyl, b-alanyl, allophanoyl, allyl, allylidene, allyloxy, amidopio, amino, aminomethyleneamino, aminooxy, ammonio, anilino, anisidino, anisoyl, anthraniloyl, anthryl, anthrylene, arginyl,
asparaginyl, aspartoyl, a-aspartyl, b-aspartyl, atropoyl, azabicyclo[2.2.1]heptyl, azelaoyl, azi, azido, azino, azo, azoxy, azulenyl, benzamido, benzeneazo, benzeneazoxy, benzoyl, 1,2-benzenedicarbonyl, 1,3-benzenedicarbonyl, 1,4-benzenedicarbonyl, benzenesulfinyl, benzenesulfonamido, benzenesulfonyle, benzenesulfonylamino, benzenetriyl, benzhydryl, benzhydrylidene, benzidino, benziloyl, benzimidazoyl, benzimidoyl, benzofuranyl, benzopyranyl, benzoquinonyl, benzo[&]thieryl, benzoazinyl, benzoazoyl, benzoyl, benzoylamino, benzoylhydrazino, benzoylimino, benzoyloxy, benzyl, benzylidene, benzylidyne, benzylxoy, benzylxocarbonyl, benzylthio, bicyclo[2.2.1]hept-5-en-2-yl, bi(cyclohexan)yl, bi(cyclohexyl)yl, binaphthalenyl, binaphthylyl, biphenylyl, biphényl, bomenyl, bornyl, bornyl, bromo, bromoformyl, bromonio, butadienyl, butanediol, butanediylidene, butanediylidene, 1,2,3-butanetricarbonyl, butanoyl, 1-butanylen-4-ylidynes, cis-butenediyl, trans-butenediyl, butenyl, 1-butenyl, 2-butenyl, 2-butenylene, butenylidene, butenylidyne, butoxy, sec-butoxy, tert-butoxy, butyl, sec-butyl, ferf-butyl, butylidene, sec-butylidene, butylidyne, butyril, camphoroyl, camphyl, carbamoyl, carbazido, carbolinyl, carbonyl, carbonimidoyl, carbonohydrazido, carboxyl, carboxylidene, carboxyl, carboxylato, carenyl, caryl, chloro, chlorocarbonyl, chloroformyl, chloronio, chlorosyl, chlorothio, chloryl, chloanthrenyl, chromanyl, chromonio, chrysenyl, cinnamoyl, cinnamyl, cinnmylidene, cinnolinyl, citraconoyl, coronenyl, crotonoyl, crotyl, cumenyl, cyanato, cyano, cyclobutyl, cycloheptyl, cyclohexadienyl, cyclohexadienylidene, cyclohexadienylidene, cyclohexanecarboxyl, cyclohexanecarboxymoidoyl, cyclohexanecarboxyimoyl, cyclohexanecarbonyl, cyclohexanecarboxthiolioyl, cyclohexanecarboxamido, cyclohexanecarboxymoidoyl, cyclohexenyl, cyclohexenylene, 2-cyclohexenylidene, cyclohexyl, cyclohexylcarbonyl, cyclohexylene, cyclohexylidene, cyclohexylthiocarbonyl, cyclopropadienyl, cyclopentadienylidene, cyclopentanespirocycolbutyl, cyclopenta[a]phenanthryl, 1,2-cyclopentenophenanthryl, cyclopentenyl, cyclopentenyldene, cyclopentyl, cyclopentylene, cyclopentylidene, cyclopropyl, cystathionyl, cysteiny1, cystyl, decanediol, decanoyl, decyl, diacetoxyiodo, diacetylamino, diaminomethyleneaminio, diazaanthryl, diazo, diazoaminio, dibenzoylamino, dichloroiodo, diethylamino, 3,4-dihydroxybenzoyl, 2,3-dihydroxybutanedioy1, dihydroxyiodo, 2,3-dihydroxypropanoyl, 3,4-dimethoxybenzoyl, 3,4-dimethoxyphenethyl, 3,4-dimethoxyphenylacetyl, dimethylamino, dimethylbenzoyl,
dioxacyclohexyl, dioxy, diphenylamino, diphenylmethyl, diphenylmethylenone, dithianaphthyl, dithio, dithiocarboxy, dithiosulfo, docosyl, dodecanoyl, dodecyl, dotriacontyl, elaidoyl, epidioxy, epidiseleno, epidithio, episeleno, epitio, epoxy, ethanedioyl, ethanediylidene, elaidoyl, ethyl, ethoxalyl, ethoxy, ethoxycarbonyl, ethyl, ethylamino, ethylene, ethylenedioxy, ethylidyne, ethylsulfonamido, ethynyl, ethynylene, fluoranthenyl, fluorenyl, fluorenylidene, fluoro, fluoroformy, formamido, formimido, formyl, formylamino, formyloxy, furanoyl, furfurylidene, furfuryl, furfuryl, furyl, furyl, 3-furylmethyl, guanidino, guanyl, heptadecyl, heptacontyl, heptacosyl, heptadecanoyl, hexamethylene, hexanamido, hexanedioyl, hexanimidoyl, hexanohydrazonoyl, hexanoylamino, hexaphenyl, hexyl, hexylidyne, hexyloxy, hippuroyl, histidyl, homocysteinyl, homoseryl, hydantoyl, hydratropoyl, hydrazinediace, hydrazine, hydroxyl, hydroxyamino, hydroxybenzoyl, hydroxybenzyl, hydroxy, hydroxyethanoyl, hydroxypropanol, hydroxypropanoyl, hydroxypropanol, hydroxypropanoyl, icosyl, imidazolidinyl, imidazolinyl, imidazolyl, imino, iminomethylamino, indacenyl, indanyld, indazolyl, indenyl, indojinyl, indonuylidene, indolizynyl, indolyl, iodo, iodoformyl, iodonio, iodoso, iodosyl, iodoxy, iodyl, isobenzofuranyl, isobutoxoy, isobutyl, isobutyridene, isobutyryl, isocarbonohydrazido, isochoromanyl, isocoumarinyl, isocrotonoyl, isocyanato, isocynano, isoheyl, isoheylidene, isoheylidyne, isoindolinyl, isoindolyl, isoleucyl, isonicotinoyl, isoxazolidinyl, isopentyl, isopentylidene, isopentylidyne, isopentylidyne, isopentylidyne, isopentylidyne, isopentylidyne, isopentylidyne, isophthaloyl, isopropenyl, isopropyloxy, isopropyl, isopropylbenzoyl, isopropylbenzyl, isopropylidene, isoincolyl, isoselenocyanato, isosemiccarbazido, isothiazolyl, isothiocyanato, isothioureido, isoureido, isovaleryl, isovaleryl, isovaleroyl, lactoyl, lanthionyl, lauroyl, leucyl, linalyl, llysyl, maleoyl, malonyl, maloyl, menthenyl, menthyl, mercapto, mesaconoyl, mesityl, mesoxalyl, mesoxalyl, mesyl, methacryloyl, methaneazo, methaneazoxo, methanesulfamido, methanesulfanyl, methanesulfonamido, methanesulfonoyl, methanoyle, methionyl, methoxalyl, methoxy,
methoxybenzoyl, methoxycarbonyl, methoxyimino, methoxyphenyl, methoxysulfinyl, methoxysulfonyl, methoxy(thiosulfonyl), methyl, a-methylacryloyl, methylallyl, methylamino, methylazo, methylaooxy, methylbenzenecarbonoyl, a-methylbenzyl, 3-methylbutanoyl, c/s-methylbutenediroy, fra/7s-methylbutenediroy, methylidithio, methylene, methylenedioxy, 3, 4-methylenedioxybenzoyl, 5-methylhexyl, methylidyne, 1-methylpentyl, 2-methylpentyl, 2-methylpropenoyl, methylsulfinimidoyl, methylsulfinohydrazonoyl, methylsulfinohydroximoyl, methylsulfinyl, methylsulfinylamino, methylsulfonimidoyl, methylsulfonohydrazonoyl, methylsulfonohydroxamoyl, methylsulfonyl, methylthio, (methylthio)sulfonyl, 1-methylvinyl, morpholino, morpholinyl, myristoyl, naphthaceny1, naphthaleneazo, naphthalene-carbonoyl, naphthalenetetrayl, naphtho[2,3-b]thienyl, naphthoyl, naphthoyloxy, naphthyf, naphthylazo, naphthylene, naphthylenebisazo, naphthylmethylene, naphthylmethylidyne, naphthyflox, naphthyridinyl, neopentyl, neryl, nicotinoyl, nitrilo, nitro, ac/-nitro, nitroso, nonacontyl, nonacosyl, nonadecyl, nonanediroyl, nonanoyl, nonyl, norbornyl, norcamphyl, norcaryl, norleucyl, norpinanyl, norvalyl, octacontyl, octacosyl, octadecanal, c/s-9-octadecenoyl, octadecyl, octanediroyl, octanoyl, octyl, oleoyl, ornithyl, ovalenyl, oxalaceto, oxalacetyl, oxa, oxalo, oxalyl, oxamoyl, oxaprenyl, oxazinyl, oxazolidinyl, oxazoliny1, oxazolyl, oxido, oxo, oxonio, oxy, palmitoyl, pentaceny1, pentacosyl, pentadecanoyl, pentadecyl, pentafluorothio, pentamethylene, pentatediroyl, pentanoyl, pentapheneyl, pentazolyl, pentenyl, 2-pent-4-enyl, pentyl, tert-pentyl, pentyldiene, pentyldyne, pentyloxy, perchloroyl, perimidinyl, perylenyl, phenacy1, phenacylidene, phenaleny1, phenanthridinyl, phenanthroliny1, phenanthryl, phenanthrylene, phenarsazinyl, phenazinyl, phenethyl, phenetidinoyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phenoxy, phenyl, phenylacetyl, phenylazo, phenylazoxy, phenylcarbrmoyl, phenylene, phenyletheny1, phenylimino, 2-phenylpropanoyl, 3-phenylpropenoyl, 3-phenylpropyl, phenylsulfinoyl, phenylsulfonyl, phenylsulfonylamino, phenylthio, 3-phenylureido, phthalamoyl, phthalazinyl, phthalidyl, phthalidyldiene, phthalimido, phthaloyl, phthyl, piceny1, picryl, pimeloyl, pinanly1, pinanyl, pinanyldene, piperezinyl, piperidinoyl, piperidyl, piperidyldiene, piperonyl, piperonyldiene, piperonyloyl, pivaloyl, pleiadenyl, polythio, prolyl, propanediroyl, propane-1,3-diyl-2-yldene, propane-1,2,3-triy1, propanoyl, propan-1-yl-3-yldene, propargyl, propenoyl, 1-propenyl, 2-propenyl, propeny1, propioloyl, propionamido, propionyl, propionylamino, propionyloxy,
In certain embodiments, Ω represents an alkyl, alkenyl, or alkynyl radical optionally substituted with hetero atoms. Suitable radicals include, but are not limited to methyl, ethyl, propyl, /so-propyl, butyl, /so-butyl, sec-butyl, terf-butyl, penyl, hexyl, vinyl, allyl, and the structures shown below:
In another embodiment, Ω represents a cyclic alkyl radical optionally substituted with heter σ atoms. Non-limiting examples of such cyclic alkyl radicals include:
In other embodiments, $\Omega$ represents an aryl or heteroaryl substituent, including but not limited to:

- Aryl substituents: 
  - Benzene derivatives: 
    - $X = F, Cl, Br, I$
    - Phenol
    - Aniline
    - Diazobenzene

- Heteroaryl substituents: 
  - Oxazole
  - Thiophene
  - Azole
In addition to the foregoing aromatic moieties, Ω may comprise fused aryl or heteroaryl rings, including but not limited to:
The foregoing radicals are merely representative of the numerous alkyl and aryl substituents which are contemplated to be suitable. Other interesting radicals for Ω include:
may further include spacer moieties linking any of the foregoing radicals to the carbon atom of the main chain, including for example spacers of the form \(-(CH_2)^a\) where "a" is an integer from 1 to 10, including, for example, \(-CH_2^-, -CH_2CH_2^-, -CH_2CH_2CH_2^-\), or \(-CH_2CH_2CH_2CH_2^-\); linear alkoxy moieties of the general form \(-(CH_2)_aO^-\) or \(-O(CH_2)_a^-\) where "a" is an integer from 1 to 10, including for example, \(-CH_2O^-\) or \(-OCH_2^-\), \(-CH_2CH_2O^-\) or \(-OCH_2CH_2^-\), \(-CH_2CH_2CH_2O^-\) or \(-OCH_2CH_2CH_2^-\); \(-O(CH_2)_aO^-\) where "a" is an integer from 1 to 10; or a moiety of the form \(-(CH_2)_bO(CH_2)_c^-\), \(-(CH_2)_bS(CH_2)_c^-\), or \(-(CH_2)_bNR^a(CH_2)_c^-\) wherein "b" and "c" are independently an integer from 0 (zero) to 10 and \(R^3\) is an alkyl, alkenyl, alkynyl, aryl, heteroaryl, or alkyl-aryl group, and the like.

In selecting suitable substituents for \(\Omega\), it may be desirable to employ biosteric substitutions for the side chains of the natural amino acids. For example, a biosterism of phenylalanine provides the interesting non-natural amino acids thienylalanine, furanylalanine, pyridinylalanine, and the like.
X may also comprise variants of the naturally occurring amino acids having inverted chirality at the α-carbon, including D-alanine, D-valine, D-leucine, D-isoleucine, D-proline, D-tryptophan, D-phenylalanine, D-methionine, D-serine, D-tyrosine, D-threonine, D-cysteine, D-asparagine, D-glutamine, D-aspartic acid, D-glutamic acid, D-lysine, D-arginine, and D-histidine; or, in the case of isoleucine and threonine, interesting non-natural amino acids are the [R,R], [S,S], [S,R], and [R,S] diastereomers.

The non-natural amino acids may also be based on the β analogs of natural amino acids as described in, for example, D. Seebach, et al., Helv. Chim. Acta 1998, 81, 932, D. Seebach, et al., Helv. Chim. Acta 1996, 79, 913, the disclosures of which are hereby incorporated by reference. The β analogs are provided by Formula II in the case where \( R_2 = \cdot \text{CH}_2 \cdot \) and \( i = 0 \).

The non-natural amino acids disclosed in U.S. Patent Application Pub. 2004/0121438 A1, the disclosure of which is hereby incorporated by reference, are contemplated to be useful in the practice of the invention. These include beta-alanine (b-Ala); 3-aminopropionic acid (Dap); 2,3-diaminopropionic acid (Dpr); 4-aminobutyric acid, epsilon-aminoisobutyric acid (Aib); epsilon-aminohexanoic acid (Aha); 5-aminovaleric acid (Ava); methylglycine (MeGly); ornithine (Om); citrulline (Cit); t-butylalanine (t-BuA); f-butylglycine (t-BuG); N-methylisoleucine (MeIle); phenylglycine (Phg); cyclohexylalanine (Cha); norleucine (Nle); 2-naphthylalanine (2-Nal); 4-chlorophenylalanine (Phe(4-Cl)); 2-fluorophenylalanine (Phe(2-F)); 3-fluorophenylalanine (Phe(3-F)); 4-fluorophenylalanine (Phe(4-F)); penicillamine (Pen); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic); beta-2-thienylalanine (Thi); methionine sulfoxide (MSO); homoarginine (hArg); N-acetyl lysine (AcLys); 2,3-diaminobutyric acid (Dab); 2,3-diaminobutyric acid (Dbu); p-aminophenylalanine (Phe(pNH2)); N-methyl valine (MeVal); homocysteine (hCys) and homoserine (hSer).

A currently preferred peptide according to Formula I is KAvaK defined by \((AA) = \text{L-lysine (K)}, (AA') = \text{L-lysine (K)}, n = 1, m = 1, X = 5-aminovaleric acid (Ava):\)
In another interesting embodiment of the peptides of formula I, AA and AA' may independently represent a non-naturally occurring amino acid of formula II, or AA and AA' may independently represent a peptide fragment comprising one or more non-naturally occurring amino acids defined by formula II. In a further embodiment, any of AA, AA', and X may further include spacer groups which are not amino acids disposed between adjacent amino acid residues. When present, the spacer groups are typically selected from substituted or unsubstituted branched or straight chain C-i-C₈ alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkyl-aryl, alkyl-aryl-alkyl, and aryl-alkyl-aryl groups, including without limitation, linear alkyl moiety of the form -(CH₂)ₐ₋ where "a" is an integer from 1 to 20, including, for example, -CH₂⁻, -CH₂CH₂⁻, -CH₂CH₂CH₂⁻, or -CH₂CH₂CH₂CH₂⁻; linear alkoxy moieties of the general form -(CH₂)ₐ₋O⁻ or -O(CH₂)ₐ₋ where "a" is an integer from 1 to 20, including for example, -CH₂O⁻ or -OCH₂⁻, -CH₂CH₂O⁻ or -OCH₂CH₂⁻, -CH₂CH₂CH₂O⁻ or -OCH₂CH₂CH₂⁻; -O(CH₂)ₐ₋O⁻ where "a" is as defined above; or a moiety of the form -(CH₂)ₐ₋O(CH₂)ₐ₋O⁻ -(CH₂)ₐ₋ or -(CH₂)₂₋S( CH₂)₂₋ or -(CH₂)₂₋NRₐ₋(CH₂)ₐ₋ wherein "b" and "c" are independently an integer from 0 (zero) to 20 and Rₐ₋ is an optionally substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, or alkyl-aryl group; and wherein the spacer group optionally includes fictionalization at either terminal end, or both terminal ends, with functional groups selected from the group consisting of -O⁻, -S⁻, -NR a⁻, -NR a⁻(C=O)⁻, -O-(C=O)⁻, -O-(C=O)-O⁻, and -O-(SO₂)⁻, and the like, where Rₐ₋ is as defined above.

In another aspect of the invention, peptides are selected from the groups consisting of: (i) peptides comprising one or more amino acids of formula II; (ii) peptides comprising only amino acids of formula II; (iii) peptides comprising one or more amino acids of formula III further including one or more spacer moieties as defined above; and (iv) peptides comprising only amino acids of formula II and further including one or more spacer moieties as defined above.
It will be understood that peptides other than those of formula I are also within the scope of the invention. For example, any peptide-containing molecule comprising at least one amino acid of formula II are contemplated to be useful in the practice of the invention.

It is well within the skill in the art to prepare peptides comprising non-natural amino acids using, for example, conventional protection and activation chemistry. Typically, the amino functionality of a first amino acid is protected with a removable amino protecting group and the carboxyl functionality of a second amino acid is protected with a removable carboxyl protecting group. Suitable amine protecting groups include, without limitation, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (t-Boc), and 9-flourenylmethoxycarbonyl (FMOC). The carboxyl group may be protected by forming an acid or base labile ester such as a methyl, ethyl, benzyl, or trimethylsilyl esters. After protection, the first and second amino acids are reacted in a suitable solvent such as water or DMF in the presence of an in situ activating agent such as N,N'-dicyclohexylcarbodiimide (DCCI), diisopropylcarbodiimide (DIPCDI), or 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDCI) to effect peptide bond formation. Reactive moieties on the side chains of either amino acid are protected with protecting groups such as tefr-butyl or benzyl for OH and SH; methyl, ethyl, tert-butyl or benzyl for carboxyl groups, 2,2,5,7,8-pentamethylchroman-6-sulphonyl for the -NHC(NH₂)=NH functionality of Arg, and trityl for the imidazole group of His. Following the coupling reaction, selective deprotection of the amino group of the first amino acid is accomplished by acid hydrolysis under conditions that do not remove the carboxyl protecting group of the second amino acid. The procedure is repeated with a additional amino protected amino acids. Solid phase synthesis, such as the well-known Merrifield method, is especially useful for synthesizing the peptides of the invention.

The invention also provides a method for screening a peptide of Formula I for a cosmeceutical activity of interest. The method comprises the steps of (1) measuring the activity of a naturally occurring peptide or peptide comprising only natural amino acids using an assay capable of quantifying said activity; (2) providing a peptide of Formula I having substantial homology to the peptide of step (1) but differing in the substitution of a non-natural amino acid based on the above-described design considerations; (3) measuring the same activity of the peptide from step (2); and (4) comparing the measured activity of the peptides from steps (1) and (3) to determine whether the peptide of step (2) has the activity of interest. Representative cosmeceutical activities include those described herein, for example, inhibition of ACE, inhibition of proteolytic enzymes, melanogenesis-stimulating properties, anti-inflammatory properties, induction of collagen and/or glycosaminoglycans synthesis, stimulation of melanogenesis, Substance P antagonism, as well as those described in U.S. Patent No. 6,043,218, the disclosure of which is hereby incorporated by reference, and other activities known in the art.

ii. Cosmetic compositions

The peptides of the invention are provided in cosmetically acceptable vehicle. The vehicle may be either hydrophobic or hydrophilic. Suitable, hydrophobic carriers include, for example, waxy non-ionic substances commonly used in cosmetics, such as esters and ethers of fatty alcohols and of fatty acids, with carbon chain length from C₄ to C₂₂, preferably from C₈ to C₁₈, and most preferably from C₁₂ to C₁₈.

Examples of a fatty hydrophobic carriers include isopropyl myristate, isopropyl palmitate, octyl palmitate, isopropyl lanolate, acetylated lanolin alcohol, the benzoate of C₂⁻C₅ alcohols, cetearyl octanoate, cetyl palmitate, myristyl myristate, myristyl lactate, cetyl acetate, propylene glycol dicaprylate/caprate, decyl olate, acetylated lanolin, stearyl heptanoate, diisostearyl malate, octyl hydroxystearate, octyl hydroxystearate, isopropyl isostearate, and the like.

Suitable hydrophilic carrier solutions can be, for example, glycols and alkoxylated glycols commonly used in cosmetics, including ethylene glycol,
diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, and the like.

The cosmetic compositions may be formulated as creams, lotions, serums, sprays, sticks and other forms known to those skilled in the art. Creams and lotions are the currently preferred product forms.

The concentration of peptides in the cosmetically acceptable vehicle may range from 1 ppb to 10,000 ppm, preferably from 10 ppb to 1,000 ppm, more preferably from 100 ppb to 100 ppm, and most preferably from 1 ppm to 100 ppm.

The cosmetic compositions will typically comprise the carrier solution described above at levels between about 0.01% and about 90% by weight, preferably between about 0.1% and about 50%, more preferably between about 0.1% and about 20%, and more preferred still between about 1% and about 10% by weight.

Optionally, the present topical composition may include one or more of the invention compositions may optionally comprise other active and inactive ingredients, including, but not limited to, excipients, fillers, emulsifying agents, antioxidants, surfactants, film formers, chelating agents, gelling agents, thickeners, emollients, humectants, moisturizers, vitamins, minerals, viscosity and/or rheology modifiers, sunscreens, keratolytics, depigmenting agents, retinoids, hormonal compounds, alpha-hydroxy acids, alpha-keto acids, anti-mycobacterial agents, antifungal agents, antimicrobials, antivirals, analgesics, lipidic compounds, anti-allergenic agents, H1 or H2 antihistamines, anti-inflammatory agents, anti-irritants, antineoplastics, immune system boosting agents, immune system suppressing agents, anti-acne agents, anesthetics, antiseptics, insect repellents, skin cooling compounds, skin protectants, skin penetration enhancers, exfollients, lubricants, fragrances, colorants, staining agents, depigmenting agents, hypopigmenting agents, preservatives, stabilizers, pharmaceutical agents, photostabilizing agents, and mixtures thereof. In addition to the foregoing, the personal care products of the invention may contain any other compound for the treatment of skin disorders.
The invention also provides a method for ameliorating and/or preventing signs of human skin photo- and intrinsic aging comprising topically applying the cosmetic compositions of the invention. The cosmetic compositions of the invention are preferably applied to affected skin areas once or twice daily for as long as is necessary to achieve desired anti-aging results.

EXAMPLES

The following examples are meant to demonstrate certain aspects of the invention in a non-limiting fashion.

Example 1

Fibronectin is a homodimer, with two subunits of MW 250K, linked by a disulfide bridge. Fibronectin binds to receptor proteins called integrins that span the cell membrane, and also binds to extracellular matrix components such as collagen, fibrin and heparin. Fibronectin is an important constituent of extracellular matrix and mediates the attachment of cells to cells and to the extracellular matrix. Fibronectin is essential for the maintenance of skin integrity. Fibronectin, important for skin repair, is increased during wound healing process. UV radiation increases the degradation of fibronectin in skin. In addition, fibronectin was found at decreased levels in the papillary dermis of aging skin. See Ray D. et al. J Biol Chem. 2006, 281:23060-5; Labat-Robert J. et al. J Photochem Photobiol B. 2000 57(2-3):113-8; Pieraggi MT et al. Ann Pathol. 1984, 4(3):185-94; Clark RA et al. J Invest Dermatol. 1982, 79(5):264-9; and Clark RA J Invest Dermatol. 1983, 81(6):475-9. Thus increasing fibronectin levels in skin cells is expected to help improve the appearance of aging skin, with respect to lines, wrinkles, texture, sagging, laxity and firmness of skin.

Normal Human Dermal Fibroblasts-Adult (Cascade Biologies) were cultured in 12-well tissue culture treated plates and treated for 72 hours in the presence or absence of test actives. Following incubation, the conditioned medium from each treatment was collected in a 1.7 ml. microcentrifuge tube and frozen at -80°C for subsequent analysis. The assay was in the format of a competitive inhibition ELISA.

Human fibronectin was pre-coated on the wells except for one row, which served as a reference. Standards and samples were pre-incubated with
polyclonal rabbit antibody to human fibronectin. The polyclonal antibody was bound to the fibronectin in the standard dilutions, and in the sample, if present. The mixture was then transferred to the human fibronectin-coated plate. Free rabbit anti-human fibronectin was bound to the fibronectin on the plate. Goat anti-rabbit IgG HRP-conjugate reacted with bound rabbit anti-fibronectin. When HRP substrate was added, a blue color developed. The reaction was stopped by the addition of an acid, changing the color to yellow. This color was quantitated using a microplate reader set at 450nm. The intensity of the color was inversely proportional to the amount of fibronectin in the original sample.

Summary of Results:

<table>
<thead>
<tr>
<th>Active Agent</th>
<th>Concentration</th>
<th>Percent Stimulation of Fibronectin over control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmitoyl Lysyl Aminovaleroyl Lysine</td>
<td>0.001%</td>
<td>21.46%*</td>
</tr>
<tr>
<td></td>
<td>0.0001%</td>
<td>27.24%*</td>
</tr>
<tr>
<td></td>
<td>0.00001%</td>
<td>28.29%*</td>
</tr>
</tbody>
</table>

*PO.05 vs. control

Our data clearly show the anti-aging benefits specific to human skin cells that can be obtained upon topical application of the peptide to aging or aged skin and/or mucous membranes. In vitro, KavaK stimulated the human fibroblasts to produce Fibronectin, a crucial and beneficial component of dermal matrix, 28% more compared to untreated control fibroblasts of the same stock. As discussed above, Fibronectin has several beneficial effects on the epidermal cells of skin, as it promotes proliferation, cell migration and differentiation - processes that are slowed down considerably with skin aging. Stimulating the epidermal cells via increased fibronectin production (by the underlying fibroblasts) can lead to improved thickness of epidermis, decreasing the appearance of fine lines, creating a more youthful appearance of the skin.

Example 2

Sirtuins are a family of NAD+-dependent deacetylase enzymes that have recently been shown to play a critical role in prolonging lifespan in a broad spectrum of organisms, including mammals (Guarente, 2005 *Mechanisms in Ageing and Devt* 126:923). In 1986, Weindruch et al (J. Nutr. 1986 116(4):641-54) reported for the first time that restricting the caloric intake of lab mice proportionally increased
their lifespan compared to a group of mice with a normal diet. The calorie-restricted mice also maintained a youthful appearance and activity levels longer, and showed delays in age-related diseases. The findings have since been accepted and extended to other animals such as yeast (Lin et al 2002 Nature 418:344), and nematode worms (Lakowski 1998 PNAS 95: 13091) and Drosophila flies (Clancy et al 2001 Science 292:104).

Research into the mechanisms of caloric restriction identified the gene Sir2 (Silent Information Regulator 2) which appears to be responsible for mediating the life-extending effects of caloric restriction (Lin et al 2000, Science 2289:2126). This gene was shown to regulate lifespan in yeast- increasing the dosage of this gene extended lifespan, and loss of function shortened it (Kaeberlein et al 1999, Genes and Devt. 13:2570-2580). SIRT1 is the human homolog of the yeast Sir2 gene and is believed to play a similar role in human cells.

SIRT1 is believed to promote cell survival by binding to the protein p53 and downregulate its activity. An interesting observation is that rodents subjected to caloric restriction are more resistant to certain stressors, like oxidative stress (Sohal and Weindruch 1996 Science 273:59, Masoro 2000 Exp Gerontol. 35:299). This has been linked to the ability of the Sir protein to negatively control p53. In yeast, Sir2 represses p53-dependent apoptosis in response to DNA damage and oxidative stress, whereas when Sir2 is mutated, it increases the sensitivity of cells to the stress response (Luo et al 2001 Cell 107:137. Vaziri et al 2001 Cell 107:149).

Oxidative stress is believed to be one of the major contributors to aging of tissues and the organism as a whole. In skin, as in other tissues, accumulation of mutations in the genomic as well as mitochondrial DNA (caused by Reactive oxygen species generated during normal metabolic activities) can lead to dysfunctional cells, this can lead to intrinsic aging of the skin. Additionally, in skin, cellular stress due to oxygen free radicals d from exposure to ultraviolet radiation and the resulting damage to proteins, membranes and DNA have been shown to play a key role in extrinsic or photoaging skin.

Thus it is anticipated that upregulation of SIRT1 expression in skin will have a protective effect, serving to extend the lifespan of skin cells and keeping them
in a young and healthy state, thus helping to improve the appearance of aging skin. Especially pertinent to skin cells is the fact that cellular longevity means escape from replicative senescence, that is, the cells are able to divide and produce more generations of daughter cells. For the dermal fibroblasts, this means prolonged and increased production of collagen, elastin, and matrix molecules such as hyaluronic acid and fibronectin, all of which are known to decrease in aged skin.

Method: Normal Human Dermal Fibroblasts - Adult (Cascade Biologies) - were cultured in 100mm dishes and treated for 24 hours with test active or vehicle control at 37°C with 5% CO2. Each of the treatment plates are harvested for protein collection from whole cell lysates.

Protein from each of the treatments were denatured and run on a SDS-PAGE gel (4 to 15% gradient). The samples were transferred to a membrane for Western blotting, a technique which is capable of detecting Sirtuin-1 and its expression level through the interaction with a primary antibody. This primary antibody then interacts with a secondary antibody that is linked to an enzyme. In a process called enzymatic chemiluminescence (ECL), the linked enzyme (i.e.- Horseradish Peroxidase or HRP) reacts with a substrate making it emit light that can be detected through exposure to film, which is developed using a ECL developing machine. The amount of emitted light is directly proportional to the amount of protein expressed in the cell lysate. Each band seen on the film can be quantified using image quantification software.

The results for the stimulation of the expression of SIRT1 protein in human fibroblasts by KavaK over control are shown below.

<table>
<thead>
<tr>
<th>Active Agent</th>
<th>Concentration</th>
<th>Percent Change in expression of SIRT1 protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmitoyl-KavaK</td>
<td>0.001%</td>
<td>102%</td>
</tr>
</tbody>
</table>

The design of the peptide itself is beneficial, as its non-natural amino acid, aminovaleric acid, makes it more resistant to breakdown by protease enzymes present in human skin so that it can remain active in the skin longer, and hence
stimulate the skin cells more efficiently as compared to peptides that are broken down easily by skin enzymes.

The patents and patent applications referenced herein are hereby incorporated by reference in their entirely.

The invention having been described by the foregoing description of the preferred embodiments, it will be understood that the skilled artisan may make modifications and variations of these embodiments without departing from the spirit or scope of the invention as set forth in the following claims.
Claims:

1. A method of ameliorating or preventing signs of human skin aging comprising topically applying to the skin a cosmetic composition comprising a peptide, said peptide including one or more non-naturally occurring amino acids.

2. The method of claim 1 wherein said peptide comprises the sequence KavaK.

3. A cosmetic composition comprising a peptide and a cosmetically acceptable vehicle, said peptide including one or more non-naturally occurring amino acids.

4. The cosmetic composition of claim 3 wherein said peptide comprises the sequence KavaK.

5. The cosmetic composition of claim 3 wherein said peptide is present in an amount from 1 ppb to 10,000 ppm.

6. A method for treating, ameliorating, and/or preventing the appearance of fine lines and wrinkles comprising topically applying to skin in need thereof a cosmetic composition comprising KavaK or a derivative thereof in an amount effective to increase fibronectin levels in skin cells.

7. A method of improving the appearance of aging skin comprising topically applying to the skin a cosmetic composition comprising KavaK or a derivative thereof in an amount effective to up-regulate SIRT1 expression.